Skip to main content

Pharma stocks underperform S&P 500 by 5% over next 6 months

Make a pick
user-generated· price

Pharma stocks underperform S&P 500 by 5% over next 6 months

Market overview

Investor uncertainty about FDA approval timelines and leadership will lead to underperformance in biotech and pharma stocks. The sector will lag broader market benchmarks.

price prediction market

Implied probability (Yes)
60%

Source: user-generated

More price markets

Browse all price markets →

No one's made a Conviction call on this yet. Be the first to call it →
Loading…